SciSparc acquires Xylo Technologies' innovative endoscopic portfolio

The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease

FDA nod to AstraZeneca’s Imfinzi plus FLOT chemotherapy for early and locally advanced gastric cancer

Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg

Dexlansoprazole delayed-release capsules are a proton pump inhibitor

Akums Drugs gets 20- year patent for "Dual Release Gastro-Resistant Composition"

The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease

AstraZeneca's imfinzi cuts death risk by 22% in early gastric cancer

OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy

IOL Chemicals receives EDQM certificate for Pantoprazole Sodium Sesquihydrate Process-III

Pantoprazole sodium is a proton pump inhibitor reduces stomach acid

Gilead and Kite to transform cancer care with new data at ESMO 2025

The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy

AstraZeneca to unveil breakthrough cancer trial results at ESMO 2025

The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types

Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment

Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion

Biostar Pharma doses first patient in Phase II/III multiregional trials of utidelone capsule